Standard BioTools (LAB) Stock Statistics & Valuation Metrics

Standard BioTools has a market cap or net worth of $402.61M. The enterprise value is $272.68M.

Standard BioTools has 379,822,270 shares outstanding. The number of shares has decreased by -2.65% in one year.

Standard BioTools’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -31.48%.

The current PE Ratio of Standard BioTools is -4.45. Standard BioTools’s PEG ratio is -0.02.

In the last 12 months, Standard BioTools had revenue of 174.43M and earned -138.88M in profits. Earnings per share was -0.52.

In the last 12 months, operating cash flow was -143.45M and capital expenditures -8.36M, giving a free cash flow of -151.81M billion.

Standard BioTools pays an annual dividend of ―, resulting in a dividend yield of ―

Standard BioTools upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.

Standard BioTools as a current ratio of 5.70, with Debt / Equity ratio of 6.99%

In the past 12 months, Standard BioTools has paid 573.00K in taxes.

Standard BioTools EV to EBITDA ratio is -4.10, with an EV/FCF ratio of -3.19.

Standard BioTools has $292.87M in cash and marketable securities with $33.00M in debt, giving a net cash position of -$259.88M billion.

Gross margin is 48.31%, with operating margin of -100.46%, and net profit margin of -79.62%.

The average price target for Standard BioTools is $2.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy